Europe Active Pharmaceutical Ingredients Market is expected to reach USD XX Bn by 2027 from USD 41.78 Bn in 2019 at a CAGR of XX % during the forecast period. The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region.
Europe Active Pharmaceutical Ingredients Market Dynamics:The active pharmaceutical ingredient is the drug component, which is responsible for producing the medicinal effects on patients. API or active pharmaceutical ingredient and excipient are two key components for drugs that are used by manufacturers. Combination therapies are used by certain drugs that include multiple active ingredients for the treatment of illness symptoms. API forms the central ingredient while the excipient is the substance that covers API and is used for delivering medication inside the human body system. Excipients are chemically inactive substances by composition and do not react with the API. Pharmaceutical companies that are into manufacturing drugs use certain pre-notified standards for determining the API strength of each drug. The standard may vary broadly from one brand to another as companies use different tests manufacturing drugs.
Europe Active Pharmaceutical Ingredients Market Segment Analysis:Europe's active pharmaceuticals market is segmented into drug type, manufacturer type, synthesis type, therapeutic area, and geography. Considering the synthesis type segment, the market for active pharmaceuticals is divided into biotech and synthetic. High R&D for novel biosimilar drugs and the shift in focus of traditional manufacturers towards biological drugs resulted in the biotech segment holding the largest segment. On the basis of drug type, the market has been divided into branded drugs, generic drugs, and over-the-counter (OTC) drugs. Higher spending on R&D activities together with the rise in drug prices have resulted in branded drugs holding the largest segment and has a huge scope of growth as well. By manufacturer type, the market diverges into merchant and captive manufacturers as merchant manufacturers have held one of the fastest-growing. A rise in outsourcing of drug molecule formulation by drug manufacturers is a major factor that has boosted the growth of the merchant manufacturer segment. In addition, drug manufacturers are choosing outsourcing options for eliminating the need of heavy investment in their manufacturing process. This has acted as another major factor to boost the high growth of merchant manufacturers in Europe. Europe is very strict about its medical facilities and rules. This has resulted in manufacturers becoming more stringent about the active pharmaceutical ingredients. The presence of some large pharmaceutical companies that manufacture drugs has resulted in market growth for active pharmaceutical ingredients in Europe. UK, Germany, and France are a few major countries that have resulted in higher demand for API and boosted the overall market growth. Key Highlights: • Europe Active Pharmaceutical Ingredients market size analysis and forecast • Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the Europe Active Pharmaceutical Ingredients Market • Europe Active Pharmaceutical Ingredients Market segmentation on the basis of synthesis type, drug type, manufacturer type, therapeutic area, and geography. • Europe Active Pharmaceutical Ingredients Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of the study • Europe Active Pharmaceutical Ingredients Market analysis and forecast for major countries has been provided. • Profiling of key industry players, their strategic perspective, market positioning, and analysis of core competencies • Competitive landscape of the key players operating in the Active Pharmaceutical Ingredients market including competitive developments, investments, and strategic expansion. For company profiles, 2019 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered. Research Methodology: The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply sides were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at a market value for European Active Pharmaceutical Ingredients market.
Key Players Operating in the Europe Active Pharmaceutical Ingredients market:• Boehringer Ingelheim GmbH • Merck • Abbvie • Sun Pharmaceuticals • Dr. Reddy’s Laboratories • Albemarle Corporation • Bristol-Myers Squibb Company • Eli Lily and Company • Vinchem • Corden Pharma • Pfizer Inc., • Novartis AG, • anofi, • Boehringer Ingelheim International GmbH, • Bristol-Myers Squibb Company, • GlaxoSmithKline plc. • Merck Sharp & Dohme Corp. • AbbVie Inc. • AstraZeneca, • BASF SE • Aurobindo Pharma • LUPIN • Mylan N.V. • Sun Pharmaceutical Industries Ltd, • Piramal Pharma Solutions Key Target Audience: • Healthcare companies • Corporate healthcare entities • Government agencies • Market research and consulting firms • Venture capitalists • Technical Students
Scope of the Active Pharmaceutical Ingredients Market Report:The research report segments Europe Active Pharmaceutical Ingredients market based on synthesis type, drug type, manufacturer type, therapeutic area and geography.
Active Pharmaceutical Ingredients Market, By Synthesis Type:• Biotech • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Synthetic
Active Pharmaceutical Ingredients Market, By Drug Type:• Branded Drugs • Generic Drugs • Over-the-counter (OTC) Drugs
Active Pharmaceutical Ingredients Market, By Manufacturer Type:• Captive Manufacturers • Merchant Manufacturers
Active Pharmaceutical Ingredients Market, By Therapeutic Area:• Cardiology • Pulmonology • Oncology • Neurology • Ophthalmology • Orthopedics • Others
Active Pharmaceutical Ingredients Market, By Geography:• Europe • UK • Germany • Italy • France • Russia • Spain • Others Geographic Analysis: • Breakdown of UK Active Pharmaceutical Ingredients Market • Breakdown of Germany Active Pharmaceutical Ingredients Market • Breakdown of Italy Active Pharmaceutical Ingredients Market • Breakdown of France Active Pharmaceutical Ingredients Market • Breakdown of Russia Active Pharmaceutical Ingredients Market • Breakdown of Spain Active Pharmaceutical Ingredients Market • Breakdown of Others Active Pharmaceutical Ingredients Market Available Customizations: Maximize Market Research offers customizations of reports according to the specific requirement of our clients
1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES & SCOPE 3.1. Market Segmentation & Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration &Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political & legal, economic and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. SYNTHESIS TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 4.1. Active Pharmaceutical Ingredients Market: Synthesis Type Movement Analysis 4.2. Biotech 4.2.1. Biotech market, 2019 – 2026 (USD billion) 4.2.2. Monoclonal antibodies 184.108.40.206. Monoclonal antibodies market, 2019 – 2026 (USD billion) 4.2.3. Recombinant proteins 220.127.116.11. Recombinant proteins market, 2019 – 2026 (USD billion) 4.2.4. Vaccines 18.104.22.168. Vaccines market, 2019 – 2026 (USD billion) 4.3. Synthetic 4.3.1. Synthetic market, 2019 – 2026 (USD billion) 5. DRUG TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 5.1. Active Pharmaceutical Ingredients Market: Drug Type Movement Analysis 5.2. Branded/Innovative Drugs 5.2.1. Branded/Innovative drugs market, 2019 – 2026 (USD billion) 5.3. Generic Drugs 5.3.1. Generic drugs market, 2019 – 2026 (USD billion) 5.4. Over-the-counter (OTC) Drugs 5.4.1. Over-the-counter market, 2019 – 2026 (USD billion) 6. MANUFACTURER TYPE ESTIMATES & TREND ANALYSIS (2019 – 2026) 6.1. Active Pharmaceutical Ingredients Market: Manufacturer Type Movement Analysis 6.2. Captive Manufacturers 6.2.1. Captive manufacturers market, 2019 – 2026 (USD billion) 6.3. Merchant Manufacturers 6.3.1. Merchant manufacturers market, 2019 – 2026 (USD billion) 7. THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS (2019 – 2026) 7.1. Active Pharmaceutical Ingredients Market: Therapeutic Area Movement Analysis 7.2. Cardiology 7.2.1. Cardiology market, 2019 – 2026 (USD billion) 7.3. Pulmonology 7.3.1. Pulmonology market, 2019 – 2026 (USD billion) 7.4. Oncology 7.4.1. Oncology market, 2019 – 2026 (USD billion) 7.5. Neurology 7.5.1. Neurology market, 2019 – 2026 (USD billion) 7.6. Ophthalmology 7.6.1. Ophthalmology market, 2019 – 2026 (USD billion) 7.7. Orthopedics 7.7.1. Orthopedics market, 2019 – 2026 (USD billion) 7.8. Others 7.8.1. Others market, 2019 – 2026 (USD billion) 8. REGIONAL ESTIMATES & TREND ANALYSIS BY SYNTHESIS TYPE, DRUG TYPE, MANUFACTURER TYPE, AND THERAPEUTIC AREA (2019 – 2026) 8.1. Active Pharmaceutical Ingredients Market Share By Region, 2019 & 2026 8.2. Europe 8.2.1. Europe active pharmaceutical ingredients market, 2019 – 2026 (USD billion) 8.2.2. UK 22.214.171.124. UK Active Pharmaceutical Ingredients market, 2019 – 2026 (USD billion) 8.2.3. Germany 126.96.36.199. Germany Active Pharmaceutical Ingredients market, 2019 – 2026 (USD billion) 8.2.4. Russia 188.8.131.52. Russia Active Pharmaceutical Ingredients market, 2019 – 2026 (USD billion) 8.2.5. France 184.108.40.206. France Active Pharmaceutical Ingredients market, 2019 – 2026 (USD billion) 8.2.6. Spain 220.127.116.11. Spain Active Pharmaceutical Ingredients market, 2019 – 2026 (USD billion) 8.2.7. Italy 18.104.22.168. Italy Active Pharmaceutical Ingredients market, 2019 – 2026 (USD billion) 8.2.8. Others 22.214.171.124. Others Active Pharmaceutical Ingredients market, 2019 – 2026 (USD billion) 9. MARKET COMPETITION ANALYSIS 9.1. Strategy Framework 9.2. Company Profiles 9.2.1. Eli Lily and Company 126.96.36.199. Company Overview 188.8.131.52. Financial Performance 184.108.40.206. Product Benchmarking 220.127.116.11. Strategic Initiatives 9.2.2. Corden Pharma 18.104.22.168. Company Overview 22.214.171.124. Financial Performance 126.96.36.199. Product Benchmarking 188.8.131.52. Strategic Initiatives 9.2.3. Boehringer Ingelheim GmbH 184.108.40.206. Company Overview 220.127.116.11. Financial Performance 18.104.22.168. Product Benchmarking 22.214.171.124. Strategic Initiatives 9.2.4. Merck & Co., Inc. 126.96.36.199. Company Overview 188.8.131.52. Financial Performance 184.108.40.206. Product Benchmarking 220.127.116.11. Strategic Initiatives 9.2.5. Abbvie 18.104.22.168. Company Overview 22.214.171.124. Financial Performance 126.96.36.199. Product Benchmarking 188.8.131.52. Strategic Initiatives 9.2.6. Vinchem 184.108.40.206. Company Overview 220.127.116.11. Financial Performance 18.104.22.168. Product Benchmarking 22.214.171.124. Strategic Initiatives 9.2.7. Sun Pharmaceuticals 126.96.36.199. Company Overview 188.8.131.52. Financial Performance 184.108.40.206. Product Benchmarking 220.127.116.11. Strategic Initiatives 9.2.8. Albemarle Corporation 18.104.22.168. Company Overview 22.214.171.124. Financial Performance 126.96.36.199. Product Benchmarking 188.8.131.52. Strategic Initiatives 9.2.9. Dr. Reddy’s Laboratories 184.108.40.206. Company Overview 220.127.116.11. Financial Performance 18.104.22.168. Product Benchmarking 22.214.171.124. Strategic Initiatives 9.2.10. Bristol-Myers Squibb Company 126.96.36.199. Company Overview 188.8.131.52. Financial Performance 184.108.40.206. Product Benchmarking 220.127.116.11. Strategic Initiatives 9.2.11. Pfizer Inc., 9.2.12. Novartis AG, 9.2.13. anofi, 9.2.14. Boehringer Ingelheim International GmbH, 9.2.15. Bristol-Myers Squibb Company, 9.2.16. GlaxoSmithKline plc. 9.2.17. Merck Sharp & Dohme Corp. 9.2.18. AbbVie Inc. 9.2.19. AstraZeneca, 9.2.20. BASF SE 9.2.121.Aurobindo Pharma 9.2.22 LUPIN 9.2.23.Mylan N.V. 9.2.24.Sun Pharmaceutical Industries Ltd, 9.2.25.Piramal Pharma Solutions